Paclitaxel, estramustine phosphate, and carboplatin in patients with advanced prostate cancer

Journal of Clinical Oncology

Volumn 19, Issue 1, 2001, Pages 44-53

  Kelly, W K ^a   Curley, T ^a   Slovin, S ^a   Heller, G ^a   McCaffrey, J ^a   Bajorin, D ^a   Ciolino, A ^a   Regan, K ^a   Schwartz, M ^a   Kantoff, P ^a   George, D ^a   Oh, W ^a   Smith, M ^a   Kaufman, D ^a   Small, E J ^a   Schwartz, L ^a   Larson, S ^a   Tong, W ^a   Scher, H ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; DOCETAXEL; ESTRAMUSTINE PHOSPHATE; ETOPOSIDE; PACLITAXEL; PROSTATE SPECIFIC ANTIGEN;

ADULT; ADVANCED CANCER; AGED; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CANCER SURVIVAL; CLINICAL TRIAL; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; HUMAN TISSUE; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; SURVIVAL TIME; THROMBOCYTOPENIA;

EID: 0035151545     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2001.19.1.44     Document Type: Article

References (32)

1. Estramustine and vinblastine: Use of prostate specific antigen as a clinical trial end point for hormone refractory prostatic cancer
2. Phase II study of estramustine and vinblastine, two microtubule inhibitors, in hormone-refactory prostate cancer
3. Phase II evaluation of oral estramustine and oral etoposide in hormone-refractory adenocarcinoma of the prostate
4. Phase II trial of 96-hour paclitaxel plus oral estramustine in metastic hormone refractory prostate cancer
5. Platinum-based chemotherapy for patients with poorly differentiated hormone-refractory prostate cancers (HRPC): Response and pathologic correlations
6. Carboplatin in advanced hormone refractory prostatic cancer patients
7. Combination regimens of paclitaxel and the platinum drugs as first-line regimens for ovarian cancer
8. A clinical and pharmacokinetic study of high-dose carboplatin, paclitaxel, granulocyte colony-stimulating factor, and peripheral blood stem cells in patients with unresectable or metastatic cancer
9. Evaluation of carboplatin pharmacokinetics in the absence and presence of paclitaxel
10. Combined antimicrotubule activity of estramustine and Taxol in human prostatic carcinoma cell lines
11. P-Glycoprotein binding and modulation of the multidrug-resistant phenotype by estramustine
12. In vivo footprinting analysis of the class I P-glycoprotein promoter in drug-sensitive and resistant cells
13. Glucocorticoids repress transcription of the hamster class I P-glycoprotein gene through an activator site occlusion mechanism
14. Clinical states in prostate cancer: Toward a dynamic model of disease progression
15. Significance of normal serum prostate-specific antigen in the follow-up period after definitive radiation therapy for prostatic cancer
16. Clinical trials in relapsed prostate cancer: Defining the target
17. Reporting results of cancer treatment
18. A new parameter for measuring metastatic bone involvement by prostate cancer: The Bone Scan Index
19. Prognostic significance of extent of disease in bone in patients with androgen independent prostate cancer
20. Carboplatin dosage: Prospective evaluation of a simple formula based on renal function
21. Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastic breast cancer
22. High-performance liquid chromatographic assay for Taxol in human plasma and urine and pharmacokinetics in a phase I trial
23. Phase I and pharmacokinetic study of paclitaxel administered weekly in patients with relapsed ovarian cancer
24. Phase I trial of docetaxel with estramustine in androgen independent prostate cancer
25. Intravenous (IV) estramustine (EMP), paclitaxel (T) and carboplatin (C) in patients with advanced prostate cancer (PC)
26. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: Recommendations from the Prostate Specific Antigen Working Group
27. Vinblastine plus oral estramustine phosphate for patients with hormone-refractory prostate cancer: A Hoosier Oncology Group and Fox Chase Network phase III trial
28. Prospective evaluation of hydrocortisone and suramin in patients with androgen-independent prostate cancer
29. Antitumor activity of suramin in hormone-refractory prostate cancer controlling for hydrocortisone treatment and flutamide withdrawal as potentially confounding variables
30. Phase II trial of oral estramustine, oral etoposide, and intravenous paclitaxel in hormone-refractory prostate cancer
31. Phase I trial of the combination of daily estramustine phosphate and intermittent docetaxel in patients with metastatic hormone refractory prostate carcinoma
32. A phase II study of docetaxel, estramustine, and low dose hydrocortisone in hormone refractory prostate cancer: CALGB 9780